39 research outputs found
Holographic Brownian Motion in Magnetic Environments
Using the gauge/gravity correspondence, we study the dynamics of a heavy
quark in two strongly-coupled systems at finite temperature: Super-Yang-Mills
in the presence of a magnetic field and non-commutative Super-Yang-Mills. In
the former, our results agree qualitatively with the expected behavior from
weakly-coupled theories. In the latter, we propose a Langevin equation that
accounts for the effects of non-commutativity and we find new interesting
features. The equation resembles the structure of Brownian motion in the
presence of a magnetic field and implies that the fluctuations along
non-commutative directions are correlated. Moreover, our results show that the
viscosity is smaller than the commutative case and that the diffusion
properties of the quark are unaffected by non-commutativity. Finally, we
compute the random force autocorrelator and verify that the
fluctuation-dissipation theorem holds in the presence of non-commutativity.Comment: 34 pages. v2: typos corrected. v3: title and abstract slightly
modified in order to better reflect the contents of the paper; footnote 3 and
one reference were also added; version accepted for publication in JHE
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: A phase II-study and historical comparison with the surgical approach
<p>Abstract</p> <p>Background</p> <p>The high complication rates of surgically implanted port catheter systems (SIPCS) represents a major drawback in the treatment of isolated liver neoplasms by hepatic arterial infusion (HAI) of chemotherapy. Interventionally implanted port catheter systems (IIPCS) have evolved into a promising alternative that enable initiation of HAI without laparatomy, but prospective data on this approach are still sparse. Aim of this study was to evaluate the most important technical endpoints associated with the use of IIPCS for the delivery of 5-fluorouracil-based HAI in patients with colorectal liver metastases in a phase 2-study, and to perform a non-randomised comparison with a historical group of patients in which HAI was administered via SIPCS.</p> <p>Methods</p> <p>41 patients with isolated liver metastases of colorectal cancer were enrolled into a phase II-study and provided with IIPCS between 2001 and 2004 (group A). The primary objective of the trial was defined as evaluation of device-related complications and port duration. Results were compared with those observed in a pre-defined historical collective of 40 patients treated with HAI via SIPCS at our institution between 1996 and 2000 (group B).</p> <p>Results</p> <p>Baseline characteristics were balanced between both groups, except for higher proportions of previous palliative pre-treatment and elevated serum alkaline phosphatase in patients of group A. Implantation of port catheters was successful in all patients of group A, whereas two primary failures were observed in group B. The frequency of device-related complications was similar between both groups, but the secondary failure rate was significantly higher with the use of surgical approach (17% vs. 50%, p < 0.01). Mean port duration was significantly longer in the interventional group (19 vs. 14 months, p = 0.01), with 77 vs. 50% of devices functioning at 12 months (p < 0.01). No unexpected complications were observed in both groups.</p> <p>Conclusion</p> <p>HAI via interventionally implanted port catheters can be safely provided to a collective of patients with colorectal liver metastases, including a relevant proportion of preatreated individuals. It appears to offer technical advantages over the surgical approach.</p
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
Filterless narrowband visible photodetectors
Wavelength selective light detection is crucial for many applications such as imaging and machine vision. Narrowband spectral responses are required for colour discrimination and current systems use broadband photodiodes combined with optical filters. This approach increases architectural complexity, and limits of the quality of colour sensing. Here we report filterless, narrowband red, green, and blue photodiodes with tuneable spectral responses. The devices have simple planar junction architectures with the photoactive layer being a solution processed mixture of either an organohalide perovskite or lead halide semiconductor, and a neutral or cationic organic molecule. The organic molecules modify the optical and electrical properties of the photodiode and facilitate narrowing charge collection narrowing of the device's external quantum efficiency. These red, green, and blue photodiodes all possess full-width-at-half-maxima of <100 nm and performance metrics suitable for many imaging applications
Improved vessel squat modeling for hydrographic and navigation applications using kinematic GNSS positioning
Using Entertaining Metaphors in the Introduction of the Case Method in a Case-Based Course
In the War Against Solid Tumors Arsenic Trioxide Need Partners
In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors